Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Moderna r&d expenses
Research and development expenses are spending on new products and technology.
Moderna's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.88B, down 24.6% year over year. For fiscal 2025 it was $3.13B, down 31.1% from the year before. The highest annual figure on record is $4.85B in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.13B | -31.1% |
| FY2024 | Dec 31, 2024 | $4.54B | -6.2% |
| FY2023 | Dec 31, 2023 | $4.85B | +47.0% |
| FY2022 | Dec 31, 2022 | $3.30B | +65.5% |
| FY2021 | Dec 31, 2021 | $1.99B | +45.3% |
| FY2020 | Dec 31, 2020 | $1.37B | +176.2% |
| FY2019 | Dec 31, 2019 | $496.00M | +9.2% |
| FY2018 | Dec 31, 2018 | $454.08M | +10.6% |
| FY2017 | Dec 31, 2017 | $410.46M | +49.4% |
| FY2016 | Dec 31, 2016 | $274.72M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $651.00M | -7.0% |
| Q1 FY2026 | Mar 31, 2026 | $649.00M | -24.2% |
| Q4 FY2025 | Dec 31, 2025 | $775.00M | -30.9% |
| Q3 FY2025 | Sep 30, 2025 | $801.00M | -29.6% |
| Q2 FY2025 | Jun 30, 2025 | $700.00M | -42.7% |
| Q1 FY2025 | Mar 31, 2025 | $856.00M | -19.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.12B | -20.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.14B | -2.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.22B | +6.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.06B | -6.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.41B | +16.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.16B | +41.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.15B | +61.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.13B | +104.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.21B | +86.9% |
| Q3 FY2022 | Sep 30, 2022 | $820.00M | +57.4% |
| Q2 FY2022 | Jun 30, 2022 | $710.00M | +68.6% |
| Q1 FY2022 | Mar 31, 2022 | $554.00M | +38.2% |
| Q4 FY2021 | Dec 31, 2021 | $648.00M | -14.6% |
| Q3 FY2021 | Sep 30, 2021 | $521.00M | +51.5% |
| Q2 FY2021 | Jun 30, 2021 | $421.00M | +177.0% |
| Q1 FY2021 | Mar 31, 2021 | $401.00M | +248.7% |
| Q4 FY2020 | Dec 31, 2020 | $759.00M | +545.2% |
| Q3 FY2020 | Sep 30, 2020 | $344.00M | +187.5% |
| Q2 FY2020 | Jun 30, 2020 | $152.00M | +18.5% |
| Q1 FY2020 | Mar 31, 2020 | $115.00M | -11.8% |
| Q4 FY2019 | Dec 31, 2019 | $117.65M | -21.8% |
| Q3 FY2019 | Sep 30, 2019 | $119.64M | +9.7% |
| Q2 FY2019 | Jun 30, 2019 | $128.31M | +22.8% |
| Q1 FY2019 | Mar 31, 2019 | $130.41M | +44.7% |
| Q4 FY2018 | Dec 31, 2018 | $150.43M | – |
| Q3 FY2018 | Sep 30, 2018 | $109.05M | – |
| Q2 FY2018 | Jun 30, 2018 | $104.48M | – |
| Q1 FY2018 | Mar 31, 2018 | $90.12M | – |
See a number that looks wrong?